← Back to Clinical Trials
Recruiting NCT04097145

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

Trial Parameters

Condition Tricuspid Regurgitation
Sponsor Edwards Lifesciences
Study Type INTERVENTIONAL
Phase N/A
Enrollment 870
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2019-12-11
Completion 2027-12-31
Interventions
Edwards PASCAL SystemOptimal Medical TherapyEdwards PASCAL System

Brief Summary

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team

Eligibility Criteria

Inclusion Criteria: * Eighteen (18) years of age or older * Despite medical therapy, per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR. * Severe or greater tricuspid regurgitation * New York Heart Association (NYHA) Class II-IVa or heart failure hospitalization in the prior 12 months * Patient is at an intermediate or greater estimated risk of mortality with tricuspid valve surgery as determined by the cardiac surgeon with concurrence by the local Heart Team * Patient is able and willing to give informed consent, follow protocol procedures, and comply with follow-up visit requirements Exclusion Criteria: * Tricuspid valve anatomy not evaluable by TTE or TEE * Tricuspid valve anatomy precludes proper device deployment and function * Patient with refractory heart failure requiring, advanced intervention (i.e. patient has or will need left ventricular assist device, or transplantation) (ACC/AHA Stage D heart failure) * Pres

Related Trials